ÂÜÀòÂÒÂ×

Susan Doleman joined Cyteir as VP of Clinical Operations in August 2019. She brings to Cyteir over 25 years of R&D experience in the biopharmaceutical industry with a proven track record of successfully leading clinical research operations from IND to registration. Prior to joining Cyteir, Susan was the Vice President of Clinical Development Operations at Replimune and prior to that she held a position as Senior Director of Clinical Operations at Epizyme where she provided leadership and oversight for the tazemetostat program in the lead indications. As part of Amgen (via acquisition of BioVex) she led the clinical team that was responsible for the licensure of talimogene laherparepvec in the US and EMEA. She was responsible for oversight of multiple phase 1 and 2 trials and the conduct of the registrational trial. Susan began her career as scientist at Children’s Hospital in Boston where she did basic research in a bone biology laboratory exploring mechanisms of bone formation for potential therapies. After transitioning to biopharma, she has held roles in research and development, regulatory affairs and clinical operations at companies such as Cytomed, Immulogic, Genzyme, TolerRx, Critical Therapeutics, and other biopharma companies. Susan earned a BA in BioChemistry from Smith College.